Microglia in multiple sclerosis: pathogenesis and therapeutic modulation
DOI:
https://doi.org/10.66636/gmj.v1.i2.a40Keywords:
multiple sclerosis, microglia, demyelination, neuroinflammation, remyelination, phagocytosis, TREM2, BTK inhibitors, chronic active lesions, neurodegenerationAbstract
Background Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system characterized by demyelination, neuroinflammation, axonal injury, and progressive neurodegeneration. Microglia, the resident innate immune cells of the brain, are central participants in these processes and act as both effectors of tissue injury and mediators of repair.
Objective To critically synthesize current neuroimmunological evidence on the role of microglia in the initiation, propagation, and partial resolution of MS pathology, with particular emphasis on demyelination, axonal injury, remyelination failure, and cognitive dysfunction, and to evaluate the therapeutic potential of targeted modulation of microglial phenotype, phagocytic capacity, and immunometabolic signaling.
Methods Analytical narrative review of contemporary peer-reviewed literature (2005–2026) on microglial biology in MS, with priority given to single-cell transcriptomic studies, mechanistic preclinical work, and recent clinical trials of microglia-modulating therapies, including brain-penetrant Bruton tyrosine kinase (BTK) inhibitors.
Results Microglia in MS exhibit substantial transcriptional and functional heterogeneity. Disease-associated states such as “microglia inflamed in MS” (MIMS) and iron-laden rim microglia of chronic active lesions sustain compartmentalized neuroinflammation and contribute to slow expansion of lesions and progressive disability. Concurrently, microglial phagocytosis of myelin debris through TREM2, MerTK, CR3, and scavenger receptors is essential for oligodendrocyte precursor maturation and remyelination. Excess intracellular myelin lipid load can convert reparative microglia into a dysfunctional, foam-like proinflammatory phenotype. Therapeutic modulation of microglia — including brain-penetrant BTK inhibition, TREM2 agonism, complement modulation, and immunometabolic interventions — has produced encouraging preclinical data and, most recently, positive phase 3 clinical evidence in non-relapsing secondary progressive MS.
Conclusion Microglia are central to both tissue injury and tissue repair in MS. Selective modulation of microglial function — rather than indiscriminate suppression — represents a biologically rational and clinically emerging strategy for limiting chronic neuroinflammation, supporting remyelination, and addressing disability progression that current peripherally-acting disease-modifying therapies leave unmet.
Keywords multiple sclerosis; microglia; demyelination; neuroinflammation; phagocytosis; remyelination; disease-associated microglia; TREM2; Bruton tyrosine kinase inhibitor; chronic active lesion
References
1. Cardona AE, Huang D, Sasse ME, Ransohoff RM. Isolation of murine microglial cells for RNA analysis or flow cytometry. Nat Protoc. 2006;1(4):1947–1951. https://doi.org/10.1038/nprot.2006.327 DOI: https://doi.org/10.1038/nprot.2006.327
2. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308(5726):1314–1318. https://doi.org/10.1126/science.1110647 DOI: https://doi.org/10.1126/science.1110647
3. VanRyzin JW, Marquardt AE, Argue KJ, et al. Microglial phagocytosis of newborn cells is induced by endocannabinoids and sculpts sex differences in juvenile rat social play. Neuron. 2019;102(2):435–449.e6. https://doi.org/10.1016/j.neuron.2019.02.006 DOI: https://doi.org/10.1016/j.neuron.2019.02.006
4. Hendrickx DAE, van Eden CG, Schuurman KG, Hamann J, Huitinga I. Staining of HLA-DR, Iba1 and CD68 in human microglia reveals partially overlapping expression depending on cellular morphology and pathology. J Neuroimmunol. 2017;309:12–22. https://doi.org/10.1016/j.jneuroim.2017.04.007 DOI: https://doi.org/10.1016/j.jneuroim.2017.04.007
5. Prinz M, Jung S, Priller J. Microglia biology: one century of evolving concepts. Cell. 2019;179(2):292–311. https://doi.org/10.1016/j.cell.2019.08.053 DOI: https://doi.org/10.1016/j.cell.2019.08.053
6. Lampron A, Larochelle A, Laflamme N, et al. Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J Exp Med. 2015;212(4):481–495. https://doi.org/10.1084/jem.20141656 DOI: https://doi.org/10.1084/jem.20141656
7. Plemel JR, Manesh SB, Sparling JS, Tetzlaff W. Myelin inhibits oligodendroglial maturation and regulates oligodendrocytic transcription factor expression. Glia. 2013;61(9):1471–1487. https://doi.org/10.1002/glia.22535 DOI: https://doi.org/10.1002/glia.22535
8. Healy LM, Perron G, Won SY, et al. MerTK is a functional regulator of myelin phagocytosis by human myeloid cells. J Immunol. 2016;196(8):3375–3384. https://doi.org/10.4049/jimmunol.1502562 DOI: https://doi.org/10.4049/jimmunol.1502562
9. Healy LM, Jang JH, Won SY, et al. MerTK-mediated regulation of myelin phagocytosis by macrophages generated from patients with MS. Neurol Neuroimmunol Neuroinflamm. 2017;4(6):e402. https://doi.org/10.1212/NXI.0000000000000402 DOI: https://doi.org/10.1212/NXI.0000000000000402
10. Remmerie A, Scott CL. Macrophages and lipid metabolism. Cell Immunol. 2018;330:27–42. https://doi.org/10.1016/j.cellimm.2018.01.020 DOI: https://doi.org/10.1016/j.cellimm.2018.01.020
11. Marschallinger J, Iram T, Zardeneta M, et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat Neurosci. 2020;23(2):194–208. https://doi.org/10.1038/s41593-019-0566-1 DOI: https://doi.org/10.1038/s41593-019-0566-1
12. Cardozo PL, Lima IBQ, Maciel EMA, et al. Synaptic elimination in neurological disorders. Curr Neuropharmacol. 2019;17(11):1071–1095. https://doi.org/10.2174/1570159X17666190603170511 DOI: https://doi.org/10.2174/1570159X17666190603170511
13. Habbas S, Santello M, Becker D, et al. Neuroinflammatory TNFα impairs memory via astrocyte signaling. Cell. 2015;163(7):1730–1741. https://doi.org/10.1016/j.cell.2015.11.023 DOI: https://doi.org/10.1016/j.cell.2015.11.023
14. Rossi S, Motta C, Studer V, et al. Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult Scler. 2014;20(3):304–312. https://doi.org/10.1177/1352458513498128 DOI: https://doi.org/10.1177/1352458513498128
15. Jurgens T, Jafari M, Kreutzfeldt M, et al. Reconstruction of single cortical projection neurons reveals primary spine loss in multiple sclerosis. Brain. 2016;139(Pt 1):39–46. https://doi.org/10.1093/brain/awv353 DOI: https://doi.org/10.1093/brain/awv353
16. Pinto MV, Fernandes A. Microglial phagocytosis — rational but challenging therapeutic target in multiple sclerosis. Int J Mol Sci. 2020;21(17):5960. https://doi.org/10.3390/ijms21175960 DOI: https://doi.org/10.3390/ijms21175960
17. Fan C, Long R, You Y, et al. A novel PADRE-Kv1.3 vaccine effectively induces therapeutic antibodies and ameliorates experimental autoimmune encephalomyelitis in rats. Clin Immunol. 2018;193:98–109. https://doi.org/10.1016/j.clim.2018.02.012 DOI: https://doi.org/10.1016/j.clim.2018.02.012
18. Wang J, Wang J, Wang J, et al. Targeting microglia and macrophages: a potential treatment strategy for multiple sclerosis. Front Pharmacol. 2019;10:286. https://doi.org/10.3389/fphar.2019.00286 DOI: https://doi.org/10.3389/fphar.2019.00286
19. Liu Y, Wu C, Hou Z, et al. Pseudoginsenoside-F11 accelerates microglial phagocytosis of myelin debris and attenuates cerebral ischemic injury through complement receptor 3. Neuroscience. 2020;426:33–49. https://doi.org/10.1016/j.neuroscience.2019.11.010 DOI: https://doi.org/10.1016/j.neuroscience.2019.11.010
20. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–1821. https://doi.org/10.1177/1352458520970841 DOI: https://doi.org/10.1177/1352458520970841
21. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein–Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296–301. https://doi.org/10.1126/science.abj8222 DOI: https://doi.org/10.1126/science.abj8222
22. Bjornevik K, Münz C, Cohen JI, Ascherio A. Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat Rev Neurol. 2023;19(3):160–171. https://doi.org/10.1038/s41582-023-00775-5 DOI: https://doi.org/10.1038/s41582-023-00775-5
23. Distéfano-Gagné F, Bitarafan S, Lacroix S, Gosselin D. Roles and regulation of microglia activity in multiple sclerosis: insights from animal models. Nat Rev Neurosci. 2023;24(7):397–415. https://doi.org/10.1038/s41583-023-00709-6 DOI: https://doi.org/10.1038/s41583-023-00709-6
24. Absinta M, Maric D, Gharagozloo M, et al. A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis. Nature. 2021;597(7878):709–714. https://doi.org/10.1038/s41586-021-03892-7 DOI: https://doi.org/10.1038/s41586-021-03892-7
25. Lerma-Martin C, Badia-i-Mompel P, Ramirez Flores RO, et al. Cell type mapping reveals tissue niches and interactions in subcortical multiple sclerosis lesions. Nat Neurosci. 2024;27(12):2354–2365. https://doi.org/10.1038/s41593-024-01796-z DOI: https://doi.org/10.1038/s41593-024-01796-z
26. van den Bosch AMR, van der Poel M, Fransen NL, et al. Profiling of microglia nodules in multiple sclerosis reveals propensity for lesion formation. Nat Commun. 2024;15(1):1667. https://doi.org/10.1038/s41467-024-46068-3 DOI: https://doi.org/10.1038/s41467-024-46068-3
27. Cignarella F, Filipello F, Bollman B, et al. TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathol. 2020;140(4):513–534. https://doi.org/10.1007/s00401-020-02193-z DOI: https://doi.org/10.1007/s00401-020-02193-z
28. Fox RJ, Bar-Or A, Traboulsee A, et al. Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis. N Engl J Med. 2025;392(19):1883–1892. https://doi.org/10.1056/NEJMoa2415988 DOI: https://doi.org/10.1056/NEJMoa2415988
29. Oh J, Bar-Or A, Cree BAC, et al. Tolebrutinib versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2025. https://doi.org/10.1056/NEJMoa2415985 DOI: https://doi.org/10.1056/NEJMoa2415985
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Irina Nazarova, Daria Nazarova, Yuliia Barbashova
This work is licensed under a Creative Commons Attribution 4.0 International License.
This article is published open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.
You are free to: share and adapt the work for any purpose, even commercially.
Conditions: provide appropriate credit to the authors and the Georgian Medical Journal (GMJ), link to the licence, and indicate if changes were made. Do not apply legal terms or technological measures that legally restrict others from doing anything the licence permits.
Licence: creativecommons.org/licenses/by/4.0 · Legal code: creativecommons.org/licenses/by/4.0/legalcode
Third-party material. Images or other content credited to a third party are not covered by CC BY 4.0; permission must be obtained from the rights holder for reuse beyond statutory exceptions.
Authors' rights. Authors retain copyright. First publication rights are granted to GMJ.
Data and code. Where provided, datasets or code may carry their own licences; please follow the licence stated in the article or repository record.
Listen on Spotify
Apple Podcasts
YouTube
Amazon Music
Castbox
Pocket Casts
LinkedIn
Facebook
X
Instagram
Substack
Bluesky
ResearchGate
